Skip to main content

Breast Cancer

Breast Cancer

Maintenance Therapy with Everolimus plus Aromatase Inhibitors in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Updated Analyses of the Phase 3 Randomized MAIN-A Trial

Breast Cancer

Patients with Metastatic Breast Cancer and the Use of Chemotherapy During End of Life

Breast Cancer

In a Real-World Setting, the RIBANNA Study Showed Diverse Population Characteristics Among Patients Who Received Ribociclib Treatment

Breast Cancer

Retrospectively Analyzing the Use of CDK4/6 Inhibitors to Treat Adult Female Patients with Metastatic Breast Cancer

Breast Cancer

Efficacy Outcomes of Platinum-Based Chemotherapy in Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Case Reports, Breast Cancer, Infusion Issues

Desensitization Permits Continued Trastuzumab and Ado-Trastuzumab Emtansine Therapy After Hypersensitivity Reaction

Anna Kempke, PharmD, BCOP, BCPS, Shawna Kraft, PharmD, BCOP, Mariana Castells, MD, PhD, Rajan Ravikumar, MD, Catherine Van Poznak, MD

Anna Kempke, PharmD, BCOP, BCPS; Shawna Kraft, PharmD, BCOP; Mariana Castells, MD, PhD; Rajan Ravikumar, MD; Catherine Van Poznak, MD

FDA Oncology Update, Breast Cancer

Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer

Case Reports, Breast Cancer

Fulvestrant- and Palbociclib-Induced Hepatotoxicity in a Patient with Breast Cancer: A Case Report

Christopher Elder, PharmD, BCOP, Zahava Ohana, PharmD, Waqar Younas, PharmD

Christopher Elder, PharmD, BCOP; Zahava Ohana, PharmD; Waqar Younas, PharmD

Breast Cancer

I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer “Graduates” to Phase 3 Study

From the Literature, Breast Cancer

Adding Tucatinib to Trastuzumab and Capecitabine Improves Survival in HER2-Positive Metastatic Breast Cancer

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

5
6
7
8
9
10
11

Page 8 of 11
Results 71 - 80 of 101